Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Olga Dashevsky, Sara Gandolfi, Olli Dufva, Ricardo De Matos Simoes, Jani Huuhtanen, Benjamin G. Barwick, Ryosuke Shirasaki, Michal Sheffer, Aidan Culhane, Jonathan D. Licht, Christine-Ivy Liacos, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Lawrence H. Boise, Francisca Vazquez, Matti Kankainen, Satu Mustjoki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2023-189570

Published: 2023

Journal Articles

Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study

Patrick Van Dreden, Loula Papageorgiou, Eleftheria Lefkou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Aurelie Rousseau, Michele Sabbah, Matthieu Grusse, Ismail Elalamy, Elisabeth Mbemba, Meletios Athanasios Dimopoulos, Grigoris Gerotziafas

Blood (2023) 142 (Supplement 1): 5404.

https://doi.org/10.1182/blood-2023-187055

Published: 2023

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Blood (2023) 142 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2023-188538

Published: 2023

Journal Articles

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Blood (2023) 142 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2023-190226

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Efstathios Kastritis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Hariklia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos

Blood (2023) 142 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2023-189521

Published: 2023

Journal Articles

Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study

Patrick Van Dreden, Loula Papageorgiou, Eleftheria Lefkou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Aurelie Rousseau, Michele Sabbah, Matthieu Grusse, Elisabeth Mbemba, Ismail Elalamy, Meletios Athanasios Dimopoulos, Grigoris Gerotziafas

Blood (2023) 142 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2023-186645

Published: 2023

Journal Articles

Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning

Meletios Athanasios Dimopoulos, Ola Landgren, David S. Siegel, Sebastian Grosicki, Albert Oriol, Rani Najdi, Chuang Li, Khalid Mezzi, Natalie Shu, Hang Quach

Blood (2023) 142 (Supplement 1): 2021.

https://doi.org/10.1182/blood-2023-190726

Published: 2023

Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Blood (2023) 142 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2023-178009

Published: 2023

Journal Articles

Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma

Konstantinos Soureas, Christos Minopoulos, Maria-Alexandra Papadimitriou, Panagiotis Malandrakis, Panagiotis Adamopoulos, Ioannis Ntanasis-Stathopoulos, Aristea-Maria Papanota, Maria Gavriatopoulou, Diamantis C Sideris, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Andreas Scorilas, Evangelos Terpos, Margaritis Avgeris

Blood (2023) 142 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2023-186495

Published: 2023

Journal Articles

Single-Cell RNA Sequencing Reveals Hypo-Responsiveness of T and NK Cells to Interferon Stimulation As an Immune Hallmark in Asymptomatic Waldenstrom's Macroglobulinemia

Yoshinobu Konishi, Romanos Sklavenitis-Pistofidis, Daniel L. Mallory, Ting Wu, Michelle P. Aranha, Junko Tsuji, Nicholas J Haradhvala, Elizabeth D. Lightbody, Katherine Towle, Laura Hevenor, Nickolas Tsakmaklis, Xiyue Wang, Alexa G Canning, Christine-Ivy Liacos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Steven P Treon, Gady Getz, Irene M. Ghobrial

Blood (2023) 142 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2023-186470

Published: 2023

Journal Articles

Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients

Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Pantelis Rousakis, Evangelos Eleutherakis-Papaiakovou, Chrysanthi Panteli, Panagiotis Malandrakis, Nikolaos Angelis, Nikolaos Kanellias, Georgia Dimitrakopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 880.

https://doi.org/10.1182/blood-2023-186259

Published: 2023

Journal Articles

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Charikleia Gakiopoulou, Erasmia Psimenou, Tina Bagratuni, Alexandra Papathoma, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 6756.

https://doi.org/10.1182/blood-2023-189926

Published: 2023

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C Minnema, Ashutosh D. Wechalekar, Elena Papachristou, Giorgos Psarros, Pieter Sonneveld, Stefan Schonland

Blood (2023) 142 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2023-185861

Published: 2023

Journal Articles

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Sireesha Asoori, Rakesh Popat, Joaquín Martínez-Lopez, Efstathios Kastritis, Larissa Brunaldi, Radhika Bansal, Andre De Menezes Silva Corraes, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Despina Fotiou, Meletios Athanasios Dimopoulos, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Thomas Martin, Brian GM Durie, Yi Lin

Blood (2023) 142 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2023-190793

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C. Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2022) 140 (Supplement 1): 1841–1843.

https://doi.org/10.1182/blood-2022-168757

Published: 2022

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C. Minnema, Ashutosh D. Wechalekar, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Stefan Schönland

Blood (2022) 140 (Supplement 1): 7294–7296.

https://doi.org/10.1182/blood-2022-169688

Published: 2022

Journal Articles

Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants

Evangelos Terpos, Margherita Rosati, Jenifer Bear, Robert Burns, Ioannis Ntanasis-Stathopoulos, Santhi Devasundaram, Maria Gavriatopoulou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, George N Pavlakis, Barbara K Felber

Blood (2022) 140 (Supplement 1): 4334–4335.

https://doi.org/10.1182/blood-2022-163521

Published: 2022

Journal Articles

Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group

Blood (2022) 140 (Supplement 1): 4386–4387.

https://doi.org/10.1182/blood-2022-163065

Published: 2022

Journal Articles

Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy

Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Nikolaos Kanellias, Asimina Papanikolaou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2022) 140 (Supplement 1): 4275–4276.

https://doi.org/10.1182/blood-2022-165403

Published: 2022

Journal Articles

The Cancer-Related Circrna Cirs-7 ( CDR1-AS ) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma

Maria Papatsirou, Christos K. Kontos, Ioannis Ntanasis-Stathopoulos, Paraskevi Karousi, Panagiotis Malandrakis, Foteini Theodorakakou, Christine Ivy Liacos, Aikaterini-Anna Liosi, Maria-Anna Kalioraki, Nefeli Mavrianou-Koutsoukou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Andreas Scorilas, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 7239–7240.

https://doi.org/10.1182/blood-2022-169779

Published: 2022

NARROW

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study

Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma

Single-Cell RNA Sequencing Reveals Hypo-Responsiveness of T and NK Cells to Interferon Stimulation As an Immune Hallmark in Asymptomatic Waldenstrom's Macroglobulinemia

Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants

Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group

Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy

The Cancer-Related Circrna Cirs-7 ( CDR1-AS ) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only